2-tert-butyl-1,3,5-trimethoxybenzene | 71745-62-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-tert-butyl-1,3,5-trimethoxybenzene
• CAS: 71745-62-5
• 化学式: C₁₃H₂₀O₃
• 分子量: 224.3
• InChiKey: LUFQXUOMDIUFBI-UHFFFAOYSA-N

物化性质

• 沸点：
  320.2±42.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,3,5-三甲氧基苯 、 叔丁基苯基碲化物 在 silver trifluoromethanesulfonate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以74%的产率得到2-tert-butyl-1,3,5-trimethoxybenzene
  参考文献：
  名称：

  Phenyltellanyl Triflate (PhTeOTf) as a Powerful Tellurophilic Activator in the Friedel–Crafts Reaction

  摘要：

  开发了一种用于有机碲化合物的高效亲电活化剂。由二溴苯基(苯基碲基)碲化物和AgOTf原位制备的苯基碲基三氟甲磺酸盐（PhTeOTf）在芳香化合物的存在下选择性地活化了各种有机碲化合物，生成了相应的Friedel-Crafts反应产物。聚合物端基有机碲化合物也能被PhTeOTf活化，提供了相应的端基功能化聚合物。

  DOI：

  10.1246/cl.2008.650

文献信息

• CYSTEINE PROTEASE INHIBITORS
  申请人：Unoki Gen

  公开号：US20090291945A1

  公开（公告）日：2009-11-26

  To provide a compound having an excellent cysteine protease inhibitory effect, and to provide a drug for treatment or prevention of the disease selected from the group consisting of osteoporosis, osteoarthritis, chronic rheumatoid arthritis, Paget's disease of bone, hypercalcemia, bone metastasis of cancer, and ostealgia. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, or a drug or pharmaceutical composition containing the same as an effective component.

  提供一种具有优异半胱氨酸蛋白酶抑制作用的化合物，并提供一种用于治疗或预防骨质疏松症、骨关节炎、慢性类风湿性关节炎、骨Paget病、高钙血症、骨癌转移和骨痛的药物。化合物由式（1）表示，或其药学上可接受的盐，或将其作为有效成分的药物或药物组合物。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Raeppel Stephane

  公开号：US20090023734A1

  公开（公告）日：2009-01-22

  The invention provides compounds and methods for treating cell proliferative diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically.

  本发明提供了治疗细胞增殖性疾病的化合物和方法。本发明提供了组成该化合物的新型组织脱乙酰化酶酶活性抑制剂，该化合物的组成物包括抑制剂和药学上可接受的载体、辅料或稀释剂，以及使用该化合物在体外和治疗上抑制细胞增殖的方法。
• Imine Compound
  申请人：Saito Shiuji

  公开号：US20080312435A1

  公开（公告）日：2008-12-18

  An imine compound represented by the formula: wherein A represents a heterocyclic group; R 1 , R 2 , an R 3 each represent a hydrogen atom, a halogen atom, a C 1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom(s), a C 3-10 cycloalkyl group, a C 1-6 haloalkyl group, a C 1-10 alkoxy group, etc.; R 4 represents an optionally substituted C 1-10 alkyl, C 2-6 alkenyl, or aryl group; R 5 represents a hydrogen atom, a C 1-10 alkoxy group, a C 1-6 haloalkyl group, an optionally substituted C 1-10 alkyl or C 2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents —CO—, —CO—CO—, —CO—NH—, —CS—NH—, or —SO 2 —, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

  一种以以下式表示的亚胺化合物：其中A代表杂环基团；R1、R2和R3分别表示氢原子、卤素原子、C1-10烷基，该烷基可选地取代有芳基，所述芳基取代有卤素原子，C3-10环烷基，C1-6卤代烷基，C1-10烷氧基等；R4表示可选地取代的C1-10烷基，C2-6烯基或芳基；R5表示氢原子，C1-10烷氧基，C1-6卤代烷基，可选地取代的C1-10烷基或C2-6烯基，可选地取代的芳基或杂环基团等；W表示—CO—，—CO—CO—，—CO—NH—，—CS—NH—或—SO2—，或以该亚胺化合物为活性成分的大麻素受体激动剂。本发明的亚胺化合物具有大麻素受体激动剂作用，可用作治疗或预防疼痛和自身免疫性疾病的药物。
• Methods to induce targeted protein degradation through bifunctional molecules
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10464925B2

  公开（公告）日：2019-11-05

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

  本申请提供了作为蛋白质降解诱导分子的双功能化合物。本申请还涉及通过使用双官能化合物靶向降解内源性蛋白质的方法，该双官能化合物将脑龙结合分子与能够与靶向蛋白质结合的配体连接起来，可用于治疗增殖性疾病。本申请还提供了制造本申请化合物及其中间体的方法。
• Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US11046954B2

  公开（公告）日：2021-06-29

  This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

  本发明属于利用靶向蛋白降解调节嵌合抗原受体免疫效应细胞（例如 T 细胞（CAR-T））疗法以调节相关不良炎症反应（例如细胞因子释放综合征和肿瘤溶解综合征）的组合物和方法领域。